Literature DB >> 24272676

NOB1 in non-small-cell lung cancer: expression profile and clinical significance.

Kun Liu1, Ming-Ming Gu, Hong-Lin Chen, Qing-Sheng You.   

Abstract

Nin one binding (NOB1) gene has been reported up-regulated in several types of cancer. The aim of this study was to investigate the expression profile of NOB1 in non-small-cell lung cancer (NSCLC) and assess the clinical significance. qRT-PCR was used in the detection of NOB1 mRNA expression both in NSCLC tissue and in adjacent normal lung tissue. Western blot analysis and immunohistochemistry were used in the detection of NOB1 protein expression. The clinicopathological implications of NOB1 were analyzed statistically. It was confirmed by RT-qPCR that expression of NOB1 mRNA in NSCLC cells was higher than in human lung cells (P < 0.05), and NOB1 mRNA was also over-expressed in NSCLC tissue when compared with adjacent tissue and normal lung tissue (P < 0.05). Western blot analysis showed that NOB1 protein was significant increased in NSCLC cell lines compared with human lung cell line. Western blot analysis and immunohistochemistry showed that NOB1 protein was significant increased in NSCLC tissue compared with adjacent tissue and normal lung tissue (P < 0.05). There were significant associations between NOB1 expression and TNM stage, lymph node metastasis, and histopathological grade (P < 0.05), but not gender, age, smoke, or tumor diameter (P > 0.05). Our results suggest that enhanced expression of NOB1 gene plays an important role in the occurrence and development of NSCLC. NOB1 may be a potential therapeutic target in NSCLC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24272676     DOI: 10.1007/s12253-013-9717-y

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  16 in total

1.  Nob1 binds the single-stranded cleavage site D at the 3'-end of 18S rRNA with its PIN domain.

Authors:  Allison C Lamanna; Katrin Karbstein
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-14       Impact factor: 11.205

2.  Downregulation of NIN/RPN12 binding protein inhibit the growth of human hepatocellular carcinoma cells.

Authors:  Zaiming Lu; Qiyong Guo; Aizhong Shi; Feng Xie; Qingjie Lu
Journal:  Mol Biol Rep       Date:  2011-05-15       Impact factor: 2.316

3.  siRNA mediated silencing of NIN1/RPN12 binding protein 1 homolog inhibits proliferation and growth of breast cancer cells.

Authors:  Wei-Yi Huang; Dong-Hui Chen; Li Ning; Li-Wei Wang
Journal:  Asian Pac J Cancer Prev       Date:  2012

4.  Non-small cell lung cancer.

Authors:  David S Ettinger; Wallace Akerley; Hossein Borghaei; Andrew C Chang; Richard T Cheney; Lucian R Chirieac; Thomas A D'Amico; Todd L Demmy; Apar Kishor P Ganti; Ramaswamy Govindan; Frederic W Grannis; Leora Horn; Thierry M Jahan; Mohammad Jahanzeb; Anne Kessinger; Ritsuko Komaki; Feng-Ming Kong; Mark G Kris; Lee M Krug; Inga T Lennes; Billy W Loo; Renato Martins; Janis O'Malley; Raymond U Osarogiagbon; Gregory A Otterson; Jyoti D Patel; Mary C Pinder-Schenck; Katherine M Pisters; Karen Reckamp; Gregory J Riely; Eric Rohren; Scott J Swanson; Douglas E Wood; Stephen C Yang; Miranda Hughes; Kristina M Gregory
Journal:  J Natl Compr Canc Netw       Date:  2012-10-01       Impact factor: 11.908

5.  Cloning, expression and characterization of the human NOB1 gene.

Authors:  Yue Zhang; Jun Ni; Guangjin Zhou; Jian Yuan; Weihua Ren; Yuxi Shan; Wenwen Tang; Long Yu; Shouyuan Zhao
Journal:  Mol Biol Rep       Date:  2005-09       Impact factor: 2.316

Review 6.  Molecular genetic tumor markers in non-small cell lung cancer.

Authors:  Tsunehiro Oyama; Toshihiro Osaki; Tetsuro Baba; Yoshika Nagata; Makiko Mizukami; Tetsuya So; Shoji Nakata; Yoshinobu Ichiki; Hidetaka Uramoto; Masakazu Sugaya; Takashi Yoshimatsu; Masaru Morita; Takeshi Hanagiri; Kenji Sugio; Toshihiro Kawamoto; Kosei Yasumoto
Journal:  Anticancer Res       Date:  2005 Mar-Apr       Impact factor: 2.480

7.  Non-small cell lung cancer, version 2.2013.

Authors:  David S Ettinger; Wallace Akerley; Hossein Borghaei; Andrew C Chang; Richard T Cheney; Lucian R Chirieac; Thomas A D'Amico; Todd L Demmy; Ramaswamy Govindan; Frederic W Grannis; Stefan C Grant; Leora Horn; Thierry M Jahan; Ritsuko Komaki; Feng-Ming Spring Kong; Mark G Kris; Lee M Krug; Rudy P Lackner; Inga T Lennes; Billy W Loo; Renato Martins; Gregory A Otterson; Jyoti D Patel; Mary C Pinder-Schenck; Katherine M Pisters; Karen Reckamp; Gregory J Riely; Eric Rohren; Theresa A Shapiro; Scott J Swanson; Kurt Tauer; Douglas E Wood; Stephen C Yang; Kristina Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2013-06-01       Impact factor: 11.908

8.  Nob1p, a new essential protein, associates with the 26S proteasome of growing saccharomyces cerevisiae cells.

Authors:  Y Tone; N Tanahashi; K Tanaka; M Fujimuro; H Yokosawa; A Toh-e
Journal:  Gene       Date:  2000-02-08       Impact factor: 3.688

9.  Cancer statistics, 2013.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2013-01-17       Impact factor: 508.702

10.  Nob1p is required for biogenesis of the 26S proteasome and degraded upon its maturation in Saccharomyces cerevisiae.

Authors:  Yoshiko Tone; Akio Toh-E
Journal:  Genes Dev       Date:  2002-12-15       Impact factor: 11.361

View more
  3 in total

1.  Evaluation of NIN/RPN12 binding protein inhibits proliferation and growth in human renal cancer cells.

Authors:  Jian-wei Jia; Ai-qin Liu; Yun Wang; Fen Zhao; Li-ling Jiao; Jun Tan
Journal:  Tumour Biol       Date:  2014-11-26

2.  Effects of NOB1 on the pathogenesis of osteosarcoma and its expression on the chemosensitivity to cisplatin.

Authors:  Leiming Luo; Yuanhui Wang; Yiran Yin; Jianhua Ge; Xiaobo Lu
Journal:  Oncol Lett       Date:  2018-01-04       Impact factor: 2.967

3.  High Expression of RIOK2 and NOB1 Predict Human Non-small Cell Lung Cancer Outcomes.

Authors:  Kun Liu; Hong-Lin Chen; Shuo Wang; Ming-Ming Gu; Xin-Ming Chen; Shuang-Long Zhang; Kang-Jun Yu; Qing-Sheng You
Journal:  Sci Rep       Date:  2016-06-27       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.